{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T20:18:42Z","timestamp":1770754722208,"version":"3.50.0"},"reference-count":17,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"8","license":[{"start":{"date-parts":[[2022,2,25]],"date-time":"2022-02-25T00:00:00Z","timestamp":1645747200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Rationale:<\/jats:title>\n            <jats:p>Multicentric Castleman disease (MCD) is a rare lymphoproliferative disorder accompanied by systemic symptoms characterized by polyclonal hypergammaglobulinemia and chronic inflammation due to overexpression of interleukin-6. Histological heterogeneity of renal involvement in MCD has been described, although the number of reports is limited. Tocilizumab, a humanized anti-interleukin-6 receptor antibody, has been reported to be effective for MCD.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Patent concerns:<\/jats:title>\n            <jats:p>A 64-year-old man experienced refractory anemia and slowly progressive renal dysfunction with proteinuria, accompanied by persistent inflammation for 11\u200ayears.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Diagnosis:<\/jats:title>\n            <jats:p>Two renal biopsies were obtained. The first biopsy performed 7\u200ayears before admission revealed non-specific interstitial inflammation, whereas the second biopsy demonstrated global sclerosis in most glomeruli and interstitial fibrosis. The patient had multiple lymphadenopathies. Cervical lymph node biopsy histological findings were compatible with plasma cell type Castleman disease. The patient had no evidence of human hepatitis virus-8 infection.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Intervention:<\/jats:title>\n            <jats:p>The patient was treated with 60\u200amg\/d prednisolone followed by 8\u200amg\/kg intravenous tocilizumab every 2\u200aweeks.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Outcome:<\/jats:title>\n            <jats:p>His anemia significantly improved, as well as a marked reduction in proteinuria and stabilization of renal function. He did not experience renal function during the 2-years follow-up period.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Lessons:<\/jats:title>\n            <jats:p>The heterogeneity of the renal manifestations of MCD sometimes makes early diagnosis difficult. We need to interpret the histological findings of the renal biopsy carefully. For advanced-stage renal diseases, tocilizumab might be an effective treatment strategy for MCD.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000028941","type":"journal-article","created":{"date-parts":[[2022,2,25]],"date-time":"2022-02-25T13:03:17Z","timestamp":1645794197000},"page":"e28941","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":2,"title":["Successful treatment with tocilizumab for refractory anemia and slowly progressive renal glomerulosclerosis in multicentric Castleman disease"],"prefix":"10.1097","volume":"101","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2464-1833","authenticated-orcid":false,"given":"Eri","family":"Sugawara","sequence":"first","affiliation":[{"name":"Department of Rheumatology, Tonan Hospital, Sapporo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Taiki","family":"Sato","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Tonan Hospital, Sapporo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshiharu","family":"Amasaki","sequence":"additional","affiliation":[{"name":"Kuriyama Red Cross Hospital, Kuriyama, Japan."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuaki","family":"Katsumata","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Tonan Hospital, Sapporo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2022,2,25]]},"reference":[{"key":"R1-20250504","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1002\/1097-0142(195607\/08)9:4<822::AID-CNCR2820090430>3.0.CO;2-4","article-title":"Localized mediastinal lymphnode hyperplasia resembling thymoma","volume":"9","author":"Castleman","year":"1956","journal-title":"Cancer"},{"key":"R2-20250504","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1182\/blood.V74.4.1360.1360","article-title":"Pathogenic significance of interleukin-6 (IL-6\/BSF-2) in Castleman's disease","volume":"74","author":"Yoshizaki","year":"1989","journal-title":"Blood"},{"key":"R3-20250504","doi-asserted-by":"crossref","first-page":"2627","DOI":"10.1182\/blood-2004-12-4602","article-title":"Humanized anti-interleukin-6 receptor antibody treatment of multicentric Castleman disease","volume":"106","author":"Nishimoto","year":"2005","journal-title":"Blood"},{"key":"R4-20250504","doi-asserted-by":"crossref","first-page":"657","DOI":"10.7326\/0003-4819-128-8-199804150-00010","article-title":"The clinical behavior of localized and multicentric Castleman disease","volume":"128","author":"Herrada","year":"1998","journal-title":"Ann Intern Med"},{"key":"R5-20250504","first-page":"423","article-title":"Interleukin-6 receptor inhibition with tocilizumab in various renal involvements associated with multicentric Castleman's disease: a report of three cases","volume":"1","author":"Komaba","year":"2008","journal-title":"NDT Plus"},{"key":"R6-20250504","doi-asserted-by":"crossref","first-page":"21","DOI":"10.3109\/s10165-011-0571-z","article-title":"Comprehensive diagnostic criteria for IgG4-related disease (IgG4-RD), 2011","volume":"22","author":"Umehara","year":"2012","journal-title":"Mod Rheumatol"},{"key":"R7-20250504","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1159\/000044943","article-title":"Castleman's disease and mesangial proliferative glomerulonephritis: the role of interleukin-6","volume":"78","author":"Lui","year":"1998","journal-title":"Nephron"},{"key":"R8-20250504","doi-asserted-by":"crossref","first-page":"E3","DOI":"10.1053\/j.ajkd.2003.09.023","article-title":"Multicentric Castleman's disease associated with glomerular microangiopathy and MPGN-like lesion: does vascular endothelial cell-derived growth factor play causative or protective roles in renal injury?","volume":"43","author":"Seida","year":"2004","journal-title":"Am J Kidney Dis"},{"key":"R9-20250504","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1097\/PAS.0000000000000575","article-title":"Multicentric Castleman disease with tubulointerstitial nephritis mimicking IGG4-related disease: two case reports","volume":"40","author":"Zoshima","year":"2016","journal-title":"Am J Surg Pathol"},{"key":"R10-20250504","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1159\/000168351","article-title":"Rapidly progressive renal failure associated with angiofollicular lymph node hyperplasia","volume":"11","author":"Tsukamoto","year":"1991","journal-title":"Am J Nephrol"},{"key":"R11-20250504","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1093\/ndt\/gfq427","article-title":"Renal involvement in Castleman disease","volume":"26","author":"El Karoui","year":"2011","journal-title":"Nephrol Dial Transplant"},{"key":"R12-20250504","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1038\/ki.1990.193","article-title":"Interleukin 6 is an autocrine growth factor for mesangial cells","volume":"38","author":"Ruef","year":"1990","journal-title":"Kidney Int"},{"key":"R13-20250504","doi-asserted-by":"crossref","first-page":"387","DOI":"10.3109\/10428190009087030","article-title":"Increased expression of vascular endothelial growth factor (VEGF) in Castleman's disease: proposed pathomechanism of vascular proliferation in the affected lymph node","volume":"38","author":"Nishi","year":"2000","journal-title":"Leuk Lymphoma"},{"key":"R14-20250504","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1016\/S0140-6736(14)60720-0","article-title":"IgG4-related disease","volume":"385","author":"Kamisawa","year":"2015","journal-title":"Lancet"},{"key":"R15-20250504","doi-asserted-by":"crossref","first-page":"e000432","DOI":"10.1136\/rmdopen-2017-000432","article-title":"Distinct features distinguishing IgG4-related disease from multicentric Castleman's disease","volume":"3","author":"Sasaki","year":"2017","journal-title":"RMD Open"},{"key":"R16-20250504","doi-asserted-by":"crossref","first-page":"232","DOI":"10.5414\/CN109273","article-title":"Tocilizumab histologically improved AA renal amyloidosis in a patient with multicentric Castleman disease: a case report","volume":"90","author":"Yamada","year":"2018","journal-title":"Clin Nephrol"},{"key":"R17-20250504","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1111\/1744-9987.12128","article-title":"Successful use of tocilizumab in a case of multicentric Castleman's disease and end-stage renal disease","volume":"18","author":"Nagai","year":"2014","journal-title":"Ther Apher Dial"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000028941","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T03:22:23Z","timestamp":1746328943000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000028941"}},"subtitle":["A case report"],"short-title":[],"issued":{"date-parts":[[2022,2,25]]},"references-count":17,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000028941","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,25]]},"assertion":[{"value":"2022-01-21","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-02-09","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}